Background

BMS recently announced a large-scale investment in AI. The rapid increase in data volume has made it difficult to keep pace using traditional R&D processes alone. Competitors are also accelerating AI adoption, creating a need for proactive response. Consequently, the company decided to implement an enterprise-wide AI platform.

Introduction to Claude

Claude, developed by Anthropic, is an AI tool built on a large language model (LLM). LLMs are trained on massive text corpora, enabling human-like language comprehension and generation. BMS plans to position Claude as a “shared intelligence platform,” allowing researchers to receive immediate answers to queries. This is expected to substantially reduce the time required for complex experimental design and literature searches.

Enhancing R&D Efficiency

By automating data cleaning, analysis, and hypothesis generation, AI can accelerate the identification of drug candidates. BMS aims to use this capability to advance the entry point into clinical development and lower associated costs. The ultimate goal is to shorten the time it takes for new therapies to reach patients.

Industry Trends and Differentiation

Major pharmaceutical companies such as Pfizer and Novartis are also expanding AI partnerships. However, BMS differentiates itself by deploying Claude as an enterprise-wide “shared” platform to integrate knowledge flow across departments. This approach can also contribute to improvements in organizational culture and data governance.

Potential Risks and Challenges

In the early stages of AI adoption, data security, privacy concerns, and the need for model validation become prominent. Additionally, changes in researchers’ usage habits and the cost of training cannot be ignored. The realized impact will depend on how these challenges are addressed.